Abstract

Purpose Continuous flow left ventricular assist devices (LVADs) have a positive effect on pulmonary hypertension (PH) that is critical for patients implanted as bridge to heart transplant (BTT). Routine right heart catheterization (RHC) for evaluation of PH is frequently done after LVAD implant. We describe the role of RHC in treatment of PH in patients with an LVAD as BTT. Methods and Materials We performed a retrospective analysis of treatment of PH based on results of RHC in patients with isolated LVAD for more than 6 months. Thirty eight patients implanted with LVAD as BTT from 2008-2012 were included. Of those, 24 patients (63%) had a pulmonary vascular resistance (PVR) >2.5 at time of implant (Group A), and 14 patients (37%) had PVR Results Average duration of support was 20.5±9.1 and 21.5±10.6 months for Group A and B, respectively (NS). Mean PVR for Group A and B are presented in table 1 . Five patients in group A required treatment of PH, by addition or up-titration of PDE-5 inhibitor, as a result of routine RHC, compared to none in Group B. There were no major complications with RHC. Conclusions There was no need for treatment of PH in patients with normal PVR at LVAD implant. None of the patients with PVR PVR > 2.5 PVR p Pre-implant 4.2±1.25 1.7±0.81 6 months 2.1±0.97 1.8±0.57 0.35 12 months 1.9±0.82 1.9±0.64 0.93 18 months 1.8±0.83 1.6±0.32 0.60

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.